Resultados de búsqueda - Ivana Gojo

Limitar resultados
  1. 1
    Immune escape and immunotherapy of acute myeloid leukemia

    Immune escape and immunotherapy of acute myeloid leukemia por Luca Vago, Ivana Gojo

    Publicado 2020
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  2. 2
    Myeloid cell factor–1 is a critical survival factor for multiple myeloma

    Myeloid cell factor–1 is a critical survival factor for multiple myeloma por Bin Zhang, Ivana Gojo, Robert G. Fenton

    Publicado 2002
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  3. 3
    Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia

    Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia por Hanna A. Knaus, Christopher G. Kanakry, Leo Luznik, Ivana Gojo

    Publicado 2017
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  4. 4
    Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias

    Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias por Lisa A. Tobin, Caroline Robert, Aaron P. Rapoport, Ivana Gojo, Maria R. Baer, Alan E. Tomkinson, Feyruz V. Rassool

    Publicado 2012
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  5. 5
    Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study

    Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study por Borislav A. Alexiev, Wenle Wang, Yi Ning, Saranya Chumsri, Ivana Gojo, William H. Rodgers, Sanford A. Stass, Xianfeng Zhao

    Publicado 2007
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  6. 6
    Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin

    Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin por Carine Robert, Pratik Nagaria, Nisha R. Pawar, Adeoluwa Adewuyi, Ivana Gojo, David J. Meyers, Philip A. Cole, Feyruz V. Rassool

    Publicado 2016
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  7. 7
    A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders

    A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fluda... por Judith E. Karp, Francis J. Giles, Ivana Gojo, Lawrence E. Morris, Jacqueline M. Greer, Bonny Johnson, Mya Thein, Mario Sznol, Jennifer A. Low

    Publicado 2007
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  8. 8
    Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome

    Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome por Ivana Gojo, Alexander E. Perl, Selina M. Luger, Maria R. Baer, Kelly J. Norsworthy, Kenneth S. Bauer, Michael Tidwell, Stephanie Fleckinger, Martin Carroll, Edward A. Sausville

    Publicado 2013
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  9. 9
    Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide

    Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclo... por Shannon R. McCurdy, Brian Iglehart, Denise Batista, Christopher D. Gocke, Yi Ning, Hanna A. Knaus, Annette M. Jackson, Mary S. Leffell, Leo Luznik, Ivana Gojo

    Publicado 2016
    Enlace del recurso
    Carta
    Agregar a favoritos
    Guardado en:
  10. 10
    Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias

    Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias por Ken Shiozawa, Takeo Nakanishi, Ming Tan, Hong-Bin Fang, Wen-chyi Wang, Martin J. Edelman, David P. Carlton, Ivana Gojo, Edward A. Sausville, Douglas D. Ross

    Publicado 2009
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  11. 11
    A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

    A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome por Mark Kirschbaum, Ivana Gojo, Stuart L. Goldberg, Christopher Bredeson, Lisa Kujawski, Allen S. Yang, Peter Marks, Paul Frankel, Xing Sun, Alessandra Tosolini, Joseph Eid, Gregory M. Lubiniecki, Jean–Pierre J. Issa

    Publicado 2014
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  12. 12
    Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy

    Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy por Hanna A. Knaus, Sofia Berglund, Hubert Hackl, Amanda L. Blackford, Joshua F. Zeidner, Raul Montiel‐Esparza, Rupkatha Mukhopadhyay, Katrina Vanura, Bruce R. Blazar, Judith E. Karp, Leo Luznik, Ivana Gojo

    Publicado 2018
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  13. 13
    Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia

    Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid... por Ivana Gojo, Ming Tan, Hong‐Bin Fang, Mariola Sadowska, Rena G. Lapidus, Maria R. Baer, France Carrier, Jan H. Beumer, Bean N. Anyang, Rahul Srivastava, Igor Espinoza‐Delgado, Douglas D. Ross

    Publicado 2013
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  14. 14
    Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

    Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide por Laura Schoch, Kenneth R. Cooke, Nina D. Wagner‐Johnston, Ivana Gojo, Lode J. Swinnen, Philip Imus, Ephraim J. Fuchs, Mark J. Levis, Richard F. Ambinder, Richard J. Jones, Douglas E. Gladstone

    Publicado 2018
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  15. 15
    Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia

    Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia por Steven D. Gore, Ivana Gojo, Mikkael A. Sekeres, Lawrence E. Morris, Marcel P. Devetten, Katarzyna Jamieson, Robert L. Redner, R.J. Arceci, Ibitayo Owoeye, Tianna Dauses, Esther Schachter-Tokarz, Robert E. Gallagher

    Publicado 2010
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  16. 16
    A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)

    A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML) por Farhad Ravandi, Ivana Gojo, Mrinal M. Patnaik, Mark D. Minden, Hagop M. Kantarjian, Amy O. Johnson‐Levonas, Craig Fancourt, Raymond W. Lam, Mary Jones, Clayton D. Knox, Shelonitda Rose, Payal Patel, Raoul Tibes

    Publicado 2016
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  17. 17
    The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing

    The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing por W. Brian Dalton, Eric Helmenstine, Lisa Pieterse, Bing Li, Christopher D. Gocke, Joshua Donaldson, Zhijian Xiao, Lukasz P. Gondek, Gabriel Ghiaur, Ivana Gojo, B. Douglas Smith, Mark J. Levis, Amy E. DeZern

    Publicado 2020
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  18. 18
    Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

    Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias por Ivana Gojo, Mariola Sadowska, Alison Walker, Eric J. Feldman, Swaminathan P. Iyer, Maria R. Baer, Edward A. Sausville, Rena G. Lapidus, Da Zhang, Yali Zhu, Ying-Ming Jou, Jennifer Poon, Karen Small, Rajat Bannerji

    Publicado 2013
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  19. 19
    A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

    A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms por Joshua F. Zeidner, J. E. Karp, Amanda L. Blackford, B. D. Smith, Ivana Gojo, Steven D. Gore, Mark J. Levis, Hetty E. Carraway, Judith M. Greer, S. Percy Ivy, Keith W. Pratz, Michael A. McDevitt

    Publicado 2013
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  20. 20
    CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo

    CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo por Leena Chaudhuri, Nicole D. Vincelette, Brian D. Koh, Ryan M. Naylor, Karen S. Flatten, Kevin L. Peterson, Andrew McNally, Ivana Gojo, Judith E. Karp, Ruben A. Mesa, Lisa Sproat, James M. Bogenberger, Scott H. Kaufmann, Raoul Tibes

    Publicado 2013
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: